Fusion antigen used as vaccine

Assignee: Healthbanks Biotech Co., Ltd.

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,595,054
App. No.: 11/948,327
Granted: Sep 29, 2009
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.

Claims (74)

1. A fusion antigen specific for a target cell comprising:

a) an antigenic moiety;

b) a ligand moiety which is capable of reacting, recognizing or binding to a receptor on the target cell;

c) a Pseudomonas exotoxin A translocation domain II; and

d) a carboxyl terminal moiety comprising a polypeptide having the amino acid sequence of KKDELRVELKDEL (SEQ ID NO: 7).

2. A fusion antigen specific for a target cell comprising:

a) an antigenic moiety comprising a polypeptide that is the translation product of a DNA fragment having the nucleotide sequence of SEQ ID NO: 2;

b) a ligand moiety capable of reacting, recognizing or binding to a receptor on the target cell;

c) a Pseudomonas exotoxin A translocation domain II; and

d) a carboxyl terminal moiety comprising a polypeptide having the amino acid sequence of KKDLRDELKDEL (SEQ ID NO: 5) or KKDELRDELKDEL (SEQ ID NO: 6).

3. The fusion antigen of claim 1 , wherein the antigenic moiety is derived from porcine reproductive and respiratory syndrome virus (PRRSV) ORF1b or ORF7.

4. The fusion antigen of claim 1 , wherein the antigenic moiety is derived from PRRSV Nsp10 and Nsp11.

5. The fusion antigen of claim 1 , wherein the antigenic moiety is derived from PRRSV ORF1b.

6. A fusion antigen specific for a target cell comprising:

a) an antigenic moiety comprising a polypeptide having the amino acid sequence of SEQ ID NO: 1;

b) a ligand moiety capable of reacting, recognizing or binding to a receptor on the target cell;

c) a Pseudomonas exotoxin A translocation domain II; and

d) a carboxyl terminal moiety comprising a polypeptide having the amino acid sequence of KDEL (SEQ ID NO: 9).

7. The fusion antigen of claim 1 , wherein the antigenic moiety comprising a polypeptide that is the translation product of a DNA fragment having the nucleotide sequence of SEQ ID NO: 2.

8. The fusion antigen of claim 1 , wherein the antigenic moiety is derived from a PRRSV protein.

9. A pharmaceutical composition comprising at least one fusion antigen according to claim 3 .

10. The fusion antigen of claim 2 , wherein the antigenic moiety is derived from PRRSV ORF1b or ORF7.

11. The fusion antigen of claim 1 , wherein the antigenic moiety is derived from PRRSV Nsp10 and Nsp11.

12. The fusion antigen of claim 1 , wherein the antigenic moiety is derived from PRRSV ORF1b.

13. The fusion antigen of claim 6 , wherein the carboxyl terminal moiety comprises the amino acid sequence of KKDELRDELKDEL(SEQ ID NO: 6) or KKDELRVELKDEL (SEQ ID NO: 7).

14. A pharmaceutical composition comprising at least one fusion antigen according to claim 13 and a pharmaceutically acceptable carrier.

15. The fusion antigen of claim 2 , wherein the antigenic moiety is derived from a PRRSV protein.

16. A pharmaceutical composition comprising at least one fusion antigen according to claim 11 .

17. The fusion antigen of claim 1 , wherein the carboxyl terminal moiety is connected to the antigenic moiety via a bridge region.

18. The fusion antigen of claim 1 , wherein the ligand moiety is a Pseudomonas exotoxin A binding domain I.

19. A pharmaceutical composition comprising one or more than one fusion antigen according to claim 1 and a pharmaceutically acceptable carrier.

20. The pharmaceutical composition of claim 19 comprising at least one fusion antigen having an antigenic moiety derived from PRRSV ORF1.

21. The pharmaceutical composition of claim 20 comprising at least one fusion antigen having an antigenic moiety derived from PRRSV ORF7.

22. The pharmaceutical composition of claim 19 comprising at least one fusion antigen having an antigenic moiety derived from PRRSV ORF7.

23. A pharmaceutical composition comprising one or more than one fusion antigen according to claim 2 and a pharmaceutically acceptable carrier.

24. The pharmaceutical composition of claim 19 comprising more than one fusion antigen, in which at least one fusion antigen comprises an antigenic moiety derived from PRRSV ORF1b.

25. The pharmaceutical composition of claim 19 comprising more than one fusion antigen, in which at least one fusion antigen comprises an antigenic moiety derived from PRRSV ORF7.

26. A method of inducing an immune response in an animal against a pathogen infection comprising the steps of:

a) providing a pharmaceutical composition according to claim 19 ; and